Tk Birkenhäger

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/5559704/publications.pdf

Version: 2024-02-01

218677 243625 2,278 82 26 citations h-index papers

g-index 88 88 88 2415 docs citations times ranked citing authors all docs

44

#	Article	IF	CITATIONS
1	Prediction of electroconvulsive therapy response and remission in major depression: meta-analysis. British Journal of Psychiatry, 2018, 212, 71-80.	2.8	196
2	Efficacy of electroconvulsive therapy in bipolar versus unipolar major depression: a metaâ€analysis. Bipolar Disorders, 2012, 14, 146-150.	1.9	172
3	Antidepressant Pharmacotherapy Failure and Response to Subsequent Electroconvulsive Therapy. Journal of Clinical Psychopharmacology, 2010, 30, 616-619.	1.4	164
4	Low-Grade Inflammation as a Predictor of Antidepressant and Anti-Inflammatory Therapy Response in MDD Patients: A Systematic Review of the Literature in Combination With an Analysis of Experimental Data Collected in the EU-MOODINFLAME Consortium. Frontiers in Psychiatry, 2019, 10, 458.	2.6	111
5	Inflammatory activation is associated with a reduced glucocorticoid receptor alpha/beta expression ratio in monocytes of inpatients with melancholic major depressive disorder. Translational Psychiatry, 2014, 4, e344-e344.	4.8	107
6	Treatment of unipolar psychotic depression: a randomized, doubleâ€blind study comparing imipramine, venlafaxine, and venlafaxine plus quetiapine. Acta Psychiatrica Scandinavica, 2010, 121, 190-200.	4.5	80
7	Circulating cytotoxic T cells and natural killer cells as potential predictors for antidepressant response in melancholic depression. Restoration of T regulatory cell populations after antidepressant therapy. Psychopharmacology, 2016, 233, 1679-1688.	3.1	79
8	ECT response in delusional versus non-delusional depressed inpatients. Journal of Affective Disorders, 2003, 74, 191-195.	4.1	68
9	TREM-1 and DAP12 expression in monocytes of patients with severe psychiatric disorders. EGR3, ATF3 and PU.1 as important transcription factors. Brain, Behavior, and Immunity, 2011, 25, 1162-1169.	4.1	67
10	Benzodiazepines for depression? A review of the literature. International Clinical Psychopharmacology, 1995, 10, 181-195.	1.7	57
11	Retrograde amnesia after electroconvulsive therapy: A temporary effect?. Journal of Affective Disorders, 2011, 132, 216-222.	4.1	53
12	Serum brain-derived neurotrophic factor level in relation to illness severity and episode duration in patients with major depression. Journal of Psychiatric Research, 2012, 46, 285-289.	3.1	43
13	Influence of age on ECT efficacy in depression and the mediating role of psychomotor retardation and psychotic features. Journal of Psychiatric Research, 2019, 109, 41-47.	3.1	39
14	Long-term Follow-up After Successful Electroconvulsive Therapy for Depression. Journal of ECT, 2007, 23, 17-20.	0.6	38
15	Fatal interaction between tranylcypromine and imipramine. European Psychiatry, 2003, 18, 264-265.	0.2	37
16	S100B Serum Levels Predict Treatment Response in Patients with Melancholic Depression. International Journal of Neuropsychopharmacology, 2016, 19, pyv103.	2.1	37
17	Effect of Antidepressant Medication Resistance on Short-term Response to Electroconvulsive Therapy. Journal of Clinical Psychopharmacology, 2004, 24, 400-403.	1.4	36
18	Influence of resistance to antidepressant pharmacotherapy on short-term response to electroconvulsive therapy. Journal of Affective Disorders, 2002, 69, 93-99.	4.1	34

#	Article	IF	CITATIONS
19	A double-blind randomized study comparing imipramine with fluvoxamine in depressed inpatients. Psychopharmacology, 2004, 175, 481-486.	3.1	34
20	Imipramine Is Effective in Preventing Relapse in Electroconvulsive Therapy-Responsive Depressed Inpatients With Prior Pharmacotherapy Treatment Failure. Journal of Clinical Psychiatry, 2006, 67, 263-268.	2.2	34
21	Can psychomotor disturbance predict ect outcome in depression?. Journal of Psychiatric Research, 2019, 117, 122-128.	3.1	33
22	Efficacy and Tolerability of Tranylcypromine Versus Phenelzine. Journal of Clinical Psychiatry, 2004, 65, 1505-1510.	2.2	33
23	Beta-blocking agents during electroconvulsive therapy: a review. British Journal of Anaesthesia, 2014, 113, 43-51.	3.4	30
24	Imipramine dose in relation to therapeutic plasma level: are clinical trials using imipramine as a positive control flawed?. Psychopharmacology, 2005, 181, 595-599.	3.1	29
25	Influence of age on the efficacy of electroconvulsive therapy in major depression: A retrospective study. Journal of Affective Disorders, 2010, 126, 257-261.	4.1	28
26	Efficacy of Tranylcypromine in Bipolar Depression. Journal of Clinical Psychopharmacology, 2015, 35, 700-705.	1.4	27
27	Influence of gender and menopausal status on antidepressant treatment response in depressed inpatients. Journal of Psychopharmacology, 2010, 24, 497-502.	4.0	26
28	Drug-free patients with major depression show an increased electrophysiological response to valid and invalid feedback. Psychological Medicine, 2011, 41, 2515-2525.	4.5	26
29	Comparison of Two-Phase Treatment With Imipramine or Fluvoxamine, Both Followed by Lithium Addition, in Inpatients With Major Depressive Disorder. American Journal of Psychiatry, 2004, 161, 2060-2065.	7.2	24
30	One-Year Outcome of Psychotic Depression After Successful Electroconvulsive Therapy. Journal of ECT, 2005, 21, 221-226.	0.6	24
31	Blood-based immune-endocrine biomarkers of treatment response inÂdepression. Journal of Psychiatric Research, 2016, 83, 249-259.	3.1	24
32	Long-term response to successful acute pharmacological treatment of psychotic depression. Journal of Affective Disorders, 2010, 123, 238-242.	4.1	22
33	The Maudsley Staging Method as predictor of electroconvulsive therapy effectiveness in depression. Acta Psychiatrica Scandinavica, 2018, 138, 605-614.	4.5	22
34	An Open Study of Triiodothyronine Augmentation of Tricyclic Antidepressants in Inpatients with Refractory Depression. Pharmacopsychiatry, 1997, 30, 23-26.	3.3	21
35	The Efficacy of Ultrabrief-Pulse (0.25 millisecond) Versus Brief-Pulse (0.50 millisecond) Bilateral Electroconvulsive Therapy in Major Depression. Journal of ECT, 2011, 27, 55-58.	0.6	21
36	One-Year Follow-Up After Successful ECT. Journal of Clinical Psychiatry, 2004, 65, 87-91.	2.2	21

#	Article	lF	CITATIONS
37	Outcome of a 4-Step Treatment Algorithm for Depressed Inpatients. Journal of Clinical Psychiatry, 2006, 67, 1266-1271.	2.2	21
38	Early improvement as a predictor of eventual antidepressant treatment response in severely depressed inpatients. Psychopharmacology, 2015, 232, 1347-1356.	3.1	19
39	Cognitive change after electroconvulsive therapy in mood disorders measured with the Montreal Cognitive Assessment. Acta Psychiatrica Scandinavica, 2020, 142, 413-422.	4.5	19
40	Efficacy of Imipramine in Psychotic Versus Nonpsychotic Depression. Journal of Clinical Psychopharmacology, 2008, 28, 166-170.	1.4	18
41	Efficacy of venlafaxine compared with tricyclic antidepressants in depressive disorder: a meta-analysis. Journal of Psychopharmacology, 2009, 23, 708-713.	4.0	14
42	Post-dexamethasone cortisol as a predictor for the efficacy of electroconvulsive therapy in depressed inpatients. Journal of Psychiatric Research, 2011, 45, 1165-1169.	3.1	14
43	A double-blind randomized study comparing plasma level-targeted dose imipramine and high-dose venlafaxine in depressed inpatients. Journal of Psychiatric Research, 2013, 47, 1337-1342.	3.1	14
44	Policy and Practice Review: A First Guideline on the Use of Pharmacogenetics in Clinical Psychiatric Practice. Frontiers in Pharmacology, 2021, 12, 640032.	3.5	14
45	Influence of episode duration of major depressive disorder on response to electroconvulsive therapy. Journal of Affective Disorders, 2006, 90, 233-237.	4.1	13
46	Influence of an adjuvant antidepressant on the efficacy of electroconvulsive therapy: A systematic review and meta-analysis. Australian and New Zealand Journal of Psychiatry, 2021, 55, 366-380.	2.3	13
47	Toward Targeted ECT. Journal of Clinical Psychiatry, 2020, 82, .	2.2	12
48	The course of depressive symptoms in unipolar depressive disorder during electroconvulsive therapy: A latent class analysis. Journal of Affective Disorders, 2010, 124, 141-147.	4.1	11
49	Improvement after two sessions of electroconvulsive therapy predicts final remission in inâ€patients with major depression. Acta Psychiatrica Scandinavica, 2019, 140, 189-195.	4.5	11
50	Psychomotor Retardation and the prognosis of antidepressant treatment in patients with unipolar Psychotic Depression. Journal of Psychiatric Research, 2020, 130, 321-326.	3.1	11
51	Interrogating Associations Between Polygenic Liabilities and Electroconvulsive Therapy Effectiveness. Biological Psychiatry, 2022, 91, 531-539.	1.3	11
52	Treatment of Unipolar Psychotic Depression. Journal of Clinical Psychopharmacology, 2009, 29, 513-515.	1.4	10
53	Tranylcypromine in Narcolepsy. Pharmacopsychiatry, 1995, 207, 98-100.	3.3	9
54	A retrospective comparison of the effects of propofol and etomidate on stimulus variables and efficacy of electroconvulsive therapy in depressed inpatients. Progress in Neuro-Psychopharmacology and Biological Psychiatry, 2013, 45, 230-235.	4.8	9

#	Article	IF	CITATIONS
55	Treatment Failure With a Tricyclic Antidepressant Followed by Lithium Addition and Response to Subsequent Electroconvulsive Therapy. Journal of Clinical Psychiatry, 2008, 69, 1887-1891.	2.2	9
56	Severe Bradycardia After Anesthesia Before Electroconvulsive Therapy. Journal of ECT, 2010, 26, 53-54.	0.6	8
57	Distinguishing Subgroups Based on Psychomotor Functioning among Patients with Major Depressive Disorder. Neuropsychobiology, 2017, 76, 199-208.	1.9	8
58	Observer-rated retardation but not agitation corresponds to objective motor measures in depression. Acta Neuropsychiatrica, 2018, 30, 359-364.	2.1	8
59	Anterograde Amnesia during Electroconvulsive Therapy: A Prospective Pilot-Study in Patients with Major Depressive Disorder. PLoS ONE, 2016, 11, e0165392.	2.5	8
60	Lithium addition in antidepressant-resistant depression: Effects on platelet 5-HT, plasma 5-HT and plasma 5-HIAA concentration. Progress in Neuro-Psychopharmacology and Biological Psychiatry, 2007, 31, 1084-1088.	4.8	7
61	Limited Evidence for Risk Factors for Proarrhythmia and Sudden Cardiac Death in Patients Using Antidepressants: Dutch Consensus on ECG Monitoring. Drug Safety, 2018, 41, 655-664.	3.2	7
62	Hair cortisol in patients with a depressive episode treated with electroconvulsive therapy. Journal of Affective Disorders, 2020, 274, 784-791.	4.1	7
63	Does power matter with ECT?. Journal of Affective Disorders, 2005, 89, 213-216.	4.1	6
64	Electroconvulsive therapy: we are hesitant to use the most effective treatment for severe depression. Acta Psychiatrica Scandinavica, 2020, 141, 301-303.	4.5	6
65	Trait Anxiety and Defensive Functioning in Relation to Antidepressant Treatment Outcome. Psychopathology, 2009, 42, 387-393.	1.5	5
66	Possible Synergy Between Electroconvulsive Therapy and Imipramine: A Case Report. Journal of Psychiatric Practice, 2016, 22, 478-480.	0.7	5
67	A randomized clinical trial comparing two two-phase treatment strategies for in-patients with severe depression. Acta Psychiatrica Scandinavica, 2017, 136, 118-128.	4.5	5
68	Performance of the Psychotic Depression Assessment Scale as a Predictor of ECT Outcome. Journal of ECT, 2019, 35, 238-244.	0.6	5
69	Association of the neutrophil to lymphocyte ratio and white blood cell count with response to pharmacotherapy in unipolar psychotic depression: An exploratory analysis. Brain, Behavior, & Immunity - Health, 2021, 16, 100319.	2.5	4
70	Cortical Inhibition and Plasticity in Major Depressive Disorder. Frontiers in Psychiatry, 2022, 13, 777422.	2.6	4
71	Influence of adjuvant nortriptyline on the efficacy of electroconvulsive therapy: a randomized controlled trial and oneâ€year followâ€up. Acta Psychiatrica Scandinavica, 2022, , .	4.5	4
72	Refractory Major Depression Successfully Treated With Electroconvulsive Therapy in a Patient With Addison Disease. Journal of ECT, 2013, 29, 137-138.	0.6	3

#	Article	IF	CITATIONS
73	Outcome of a three-phase treatment algorithm for inpatients with melancholic depression. Progress in Neuro-Psychopharmacology and Biological Psychiatry, 2018, 84, 214-220.	4.8	3
74	Prevalence of trait anxiety in a sample of depressed inpatients and its influence on response to antidepressants. Journal of Psychopharmacology, 2010, 24, 559-563.	4.0	2
75	Beta-Blocking Agents and Electroconvulsive Therapy. Current Drug Therapy, 2007, 2, 121-126.	0.3	1
76	Time-Dependent Clearance Decrements of Fluvoxamine in Depressed Inpatients. Journal of Clinical Psychopharmacology, 2007, 27, 231-233.	1.4	1
77	Response after Infection-Associated Rise in Clozapine Levels in Treatment-Resistant Schizoaffective Disorder. Case Reports in Psychiatry, 2018, 2018, 1-4.	0.5	1
78	No Causal Relation Between Bupropion in Therapeutic Dose and Serotonin Toxicity. Journal of Medical Toxicology, 2020, 16, 333-334.	1.5	1
79	Reply to Dr Baldessarini's Comments on "Efficacy of Imipramine in Psychotic Versus Nonpsychotic Depression". Journal of Clinical Psychopharmacology, 2008, 28, 717-718.	1.4	O
80	Postelectroconvulsive therapy evaluation and prophylaxis., 2009,, 505-514.		0
81	Lithium addition to a tricyclic antidepressant results in optimal efficacy. Acta Psychiatrica Scandinavica, 2011, 123, 83-83.	4.5	O
82	Does a Positive Response to Lithium Augmentation in Resistant Major Depression Indicate a Bipolar Disorder?. Journal of Clinical Psychopharmacology, 2021, 41, 202-204.	1.4	0